Compare Adaptive Biotechnologies Corp (ADPT) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cisco Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Cisco Systems Inc trades at $113.82 (market cap $440.61B). The key difference: Cisco Systems Inc is far larger — about 132.3× Adaptive Biotechnologies Corp's market cap, and Cisco Systems Inc pays a 1.5% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CSCO | |
|---|---|---|
Market Cap | $3.33B | $440.61B |
Sector | Health | Technology |
52-Week High | $22.37 | $130.00 |
52-Week Low | $10.24 | $66.20 |
Enterprise Value | $3.19B | $455.28B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Cisco Systems (CSCO) trades at $113.98, up 1.14% on the day, with a technical picture showing bearish momentum indicators but recent positive earnings beats. The company reported Q1 2026 EPS of $1.06, beating expectations of $1.03, continuing a trend of outperformance. Recent news highlights Cisco's strategic push into AI cybersecurity, announcing new software tools and partnerships at Cisco Live 2026. Valuation metrics appear elevated with a P/E of 37.99 and P/S of 7.48, though profitability remains strong with a 64.33% gross margin.
The outlook balances strong analyst support (52% buy ratings with $130.38 consensus target) against high valuation multiples and mixed technical signals. Investment opportunity centers on Cisco's AI infrastructure and cybersecurity positioning, while risks include execution in transitioning growth drivers, competitive pressures, and potential margin compression if revenue growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
